Texila International Journal of Public Health
ISSN: 2520-3134
DOI: 10.21522/TIJPH.2013.12.04.Art078

Assessment of Drug Safety Governance in Guyana: Insights from Published Research

Erica Ann Albertina Ward[1*], S. P. Sreekala[2]
[1]*College of Business Management, Texila American University, Lot 2442, Plantation Providence, East Bank Demerara (EBD), Guyana, South America*
[2]*KPR College of Arts Science and Research, Coimbatore, India*

Abstract

Developing countries like Guyana face unique challenges in ensuring drug supply safety due to limited resources, weak regulatory systems, and inadequate surveillance infrastructure. This paper presents a literature-based evaluation of drug safety oversight in Guyana. The evaluation identifies significant gaps and challenges within Guyana's regulatory agencies, including resource constraints, insufficient surveillance infrastructure, and enforcement weaknesses. Limited specific literature on Guyana highlights the need for empirical studies to assess the effectiveness of its drug regulatory systems. Through a systematic literature review, this study identifies key areas for improving drug safety oversight, emphasizing enhanced resource allocation, capacity-building initiatives, and robust regulatory frameworks. These findings emphasize the importance of strengthening regulatory systems in developing countries to ensure public health and access to safe pharmaceuticals. This evaluation offers insights for policymakers, healthcare professionals, and stakeholders involved in public health governance, facilitating evidence-based strategies to enhance drug safety oversight and regulatory effectiveness in Guyana.

Keywords: *Drug Regulatory Systems, Drug Safety, Developing Countries, Drug Quality Control, Guyana, Pharmaceutical Regulation, Public Health Governance, Regulatory Effectiveness, Regulatory Challenges.*

Introduction

Drug regulatory frameworks are systems of rules, guidelines, and practices established to ensure the safety, efficacy, and quality of pharmaceutical products, crucial for protecting public health by preventing the distribution of unsafe or ineffective drugs [1]. A drug regulatory framework encompasses all regulatory activities involved in the oversight of pharmaceuticals, from their development through to their marketing and post-market surveillance [48]. According to Mahady [36], a robust regulatory framework includes the establishment of laws and guidelines, the implementation of quality control measures, and the enforcement of compliance, ensuring that pharmaceutical products meet the required standards before reaching consumers. The regulation of drugs ensures patient safety by preventing the sale of harmful or substandard medications. Effective drug regulation reduces the risk of adverse drug reactions and medication errors, which can have severe health consequences [48]. Drug regulation also fosters pharmaceutical innovation by setting clear guidelines and standards, encouraging companies to invest in research and development, leading to the development of new and improved medicines [18]. Significant events and legislative milestones, starting with early efforts often reactive to public health crises, mark the history of drug regulatory frameworks. The 1906 Pure Food and Drug

Received: 23.09.2024 ***Accepted: 08.11.2024*** ***Published on: 27.12.2024***
****Corresponding Author: erica2ward@gmail.com***

Act in the United States was enacted in response to concerns about the safety and labelling of food and drugs [28]. The thalidomide disaster of the early 1960s, which led to severe birth defects, underscored the need for more stringent testing and evaluation of drugs before marketing, prompting stricter regulatory requirements such as the 1962 Kefauver-Harris Amendments [7]. The evolution of drug regulatory frameworks continued with international harmonization efforts, such as the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) in 1990, which aimed to streamline the drug development process by aligning regulatory standards across regions [30]. More recently, the focus has shifted towards post-market surveillance and pharmacovigilance, recognizing that monitoring drug safety does not end with market approval, with advances in technology and data analytics enhancing the ability to track adverse drug reactions and identify safety issues in real-time [18]. These developments have enhanced the ability of regulatory agencies to respond swiftly to emerging safety concerns and protect public health. Through a shift from reactive measures to proactive and harmonized approaches [36, 48, 16, 28, 7, 30]. Overall, drug regulatory frameworks are essential for ensuring the safety, efficacy, and quality of pharmaceutical products, protecting patients, maintaining public trust, and fostering innovation.

Understanding the Drug Regulatory Framework in Guyana: A Comprehensive Overview

The regulatory framework for drug safety in Guyana is a multifaceted system that involves a diverse array of stakeholders, each playing a crucial role in ensuring the safety, efficacy, and quality of the pharmaceuticals available to the public. At the core of this framework is the Government Analyst Food and Drug Department (GA-FDD) operating under the Ministry of Health, which oversees the registration, inspection, testing, and pharmacovigilance of pharmaceuticals and medical devices [72]. The GA-FDD serves as the primary regulatory authority responsible for enforcing drug safety regulations and overseeing various aspects of the pharmaceutical industry. The Food and Drugs Act enacted in 1971 and supporting regulations of 1977 govern all of the regulatory activities performed by the Government Analyst Food and Drug Department.

The transition from the "Sale of Food and Drugs Ordinance to the Food and Drugs Act in 1971 marked a significant shift in Guyana's pharmaceutical industry, granting the Minister of Health extensive authority to regulate various aspects of drug control [72]. The Food and Drugs Act of 1971 introduced centralized control over raw materials and finished drug products [72]. It also prioritized the procurement of safe, high-quality, and effective drugs and medical devices, aligned with international standards and best practices [72].

Despite the efforts of the GA-FDD, Guyana's pharmaceutical sector continues to face challenges related to drug access and control. The existing regulatory framework is characterized by a lack of comprehensive national drug policies, inefficient drug selection processes, limited financial resources, and instances of irrational drug use [51].

To address these challenges, the GA-FDD employs several mechanisms to ensure drug safety. The registration process ensures that all pharmaceuticals marketed in Guyana meet stringent quality and safety standards before being made available to the public, preventing the circulation of substandard or potentially harmful products. Import and export control regulations aim to prevent the entry of counterfeit and substandard products into the Guyanese market. Quality control protocols

and regular inspections throughout the pharmaceutical supply chain maintain the quality and integrity of pharmaceutical products. Additionally, the pharmacovigilance system allows for the monitoring of drug safety post-marketing, enabling the identification and mitigation of any unforeseen adverse effects [73].

In addition to government agencies like the GA-FDD, Guyana's drug regulatory framework encompasses a broader network of stakeholders, each playing a crucial role in ensuring the safety, efficacy, and accessibility of pharmaceuticals. Non-governmental organizations (NGOs) are vital in advocating for public health and promoting access to safe and affordable medicines. They collaborate with government agencies and other stakeholders to raise awareness about drug safety, educate vulnerable populations, and advocate for policy reforms to strengthen regulatory frameworks [11].

Healthcare professionals, including doctors, pharmacists, nurses, and allied healthcare workers, are integral to Guyana's drug regulatory framework. They prescribe, dispense, and administer pharmaceuticals, monitor patients for adverse drug reactions, and report any concerns [46]. Pharmacists, particularly those in hospital settings, play a critical role in adverse drug reaction reporting due to the higher incidence of serious reactions in these environments. Clinical pharmacologists also contribute significantly by monitoring medicine use, identifying and responding to safety issues, determining causation, and conducting post-marketing surveillance [69].

Pharmaceutical companies operating in Guyana are responsible for manufacturing, importing, and distributing pharmaceutical products. They must adhere to stringent regulatory requirements set by agencies like the GA-FDD, ensuring their products meet quality, safety, and efficacy standards before reaching the public [24].

Consumer groups play a vital role in healthcare by advocating for patient rights, drug safety, and access to healthcare. They represent the interests of patients and consumers, ensuring their voices are heard in policy decisions. These groups collaborate with various stakeholders, including government agencies, NGOs, and international organizations, to raise awareness about drug safety, provide support to individuals, and advocate for policy reforms [27].

Despite the collaborative efforts of these stakeholders, Guyana's drug regulatory framework faces challenges such as outdated legislation and limited resources. However, recent initiatives, including joining the Caribbean Regulatory System and adopting the Pan American Health Organization's Emergency Use Authorization procedure during the COVID-19 pandemic, demonstrate a proactive approach to enhancing drug safety and regulatory oversight. Additionally, Guyana's participation in the WHO Certification Scheme has improved its drug regulatory and review process, ensuring alignment with international standards [12].

A Comparative Review of Regulatory Frameworks and Practices in the Caribbean and Latin American Region

The Caribbean and Latin American regions exhibit diverse pharmaceutical regulatory frameworks shaped by distinct historical, economic, and political contexts. These regions face common challenges such as limited regulatory capacity, inconsistent enforcement, and varying levels of adherence to international standards. This comparative review aims to explore the regulatory landscapes of these regions, highlighting both strengths and areas needing improvement. The studies examined offer insights into the effectiveness of existing regulatory practices, the impact of regulatory frameworks on drug safety and availability, and the role of international collaboration in addressing

common challenges. By understanding the regulatory environments of countries in these regions, this review seeks to provide a foundation for developing more cohesive and effective regulatory strategies, particularly for countries like Guyana, which are working to strengthen their pharmaceutical regulation systems. The following summaries present key findings and recommendations from recent studies on pharmaceutical regulation in the Caribbean and Latin American regions.

Ekeigwe [19] examined drug regulation and control in developing countries, particularly focusing on the Caribbean region. Through a case study approach, the research provided an in-depth review of regulatory practices and challenges faced by several Caribbean nations. Ekeigwe highlighted significant issues such as insufficient regulatory infrastructure, limited funding, and difficulties in combating counterfeit drugs, all of which negatively impacted drug safety and efficacy in the region. The study concluded that resolving these problems requires a multifaceted approach, including the strengthening of regulatory frameworks, increasing financial resources, and enhancing regional cooperation. The study suggested implementing comprehensive regulatory reforms, improving surveillance systems, and fostering collaboration among Caribbean nations to enhance drug regulation and control.

Hewitt and Forde [27]. Investigated the pharmaceutical sector in the Caribbean, emphasizing the challenges and opportunities for improvement. Using a qualitative research design, which included interviews with industry stakeholders and a review of policy documents, the authors identified several obstacles such as regulatory inefficiencies, high medication costs, and limited access to essential drugs. These issues were further complicated by inadequate infrastructure and limited regional coordination. Hewitt and Forde concluded that overcoming these challenges required a strategic approach, including better regulatory processes, enhanced regional cooperation, and infrastructure investment. Their suggestions included developing regional pharmaceutical policies, improving supply chain management, and increasing collaboration between the public and private sectors to strengthen the Caribbean's pharmaceutical sector.

MacGillivray [35] analyzed the progress and challenges in pharmaceutical regulatory frameworks across the Caribbean using a mixed-methods approach that incorporated both quantitative data from regulatory reports and qualitative insights from interviews with regulatory officials. MacGillivray found that despite notable progress in regulatory practices, challenges such as inconsistent enforcement, limited resources, and inadequate infrastructure persisted. The study emphasized the need for continued reforms and regional cooperation to address these issues. MacGillivray concluded that advancing pharmaceutical regulation in the Caribbean required sustained efforts to enhance regulatory capacity, streamline processes, and foster regional collaboration. Recommendations included developing standardized regulatory practices and improving cross-border coordination to address the region's regulatory challenges.

Medina [37] provided an overview of current drug regulatory frameworks in the Caribbean. The study utilized a comprehensive review of regulatory policies and practices, supplemented by interviews with key stakeholders in the pharmaceutical sector. Medina identified both strengths and weaknesses in the existing frameworks, noting that while some countries had developed robust regulatory systems, others faced significant challenges such as outdated regulations and limited regulatory capacity. The study found that inconsistencies in regulatory practices across the region affected drug safety and availability. Medina concluded that to improve drug regulation in the

Caribbean, there needed to be a concerted effort to harmonize regulations, enhance regulatory infrastructure, and improve regional cooperation. Recommendations included updating regulatory frameworks to align with international standards and investing in capacity-building initiatives for regulatory bodies.

Morris [39] addressed the challenges faced by Caribbean countries in improving drug regulation. Using a descriptive research design, the study analyzed regulatory developments across various Caribbean nations through a literature review and policy analysis. Morris identified common issues such as inadequate infrastructure, insufficient funding, and lack of harmonized regulations among Caribbean nations. The study found that while efforts were being made to address these challenges, progress was uneven and slow. Morris concluded that addressing the regulatory issues in the Caribbean required enhanced regional cooperation, increased investment in regulatory infrastructure, and more robust policy frameworks. Recommendations included strengthening regional regulatory bodies and adopting more consistent regulatory standards across the Caribbean to improve drug safety and access.

Nicolosi and Mastroianni [41] explored the role of regulatory authorities in Latin America in ensuring drug safety and efficacy. The study employed a qualitative approach, including a review of regulatory frameworks and interviews with regulatory officials across the region. Nicolosi and Mastroianni identified key challenges such as variability in regulatory standards, insufficient resources, and gaps in enforcement. The study found that while regulatory authorities in Latin America played a crucial role in drug safety, there was significant room for improvement in terms of consistency and effectiveness. The study concluded that to enhance drug regulation in Latin America, there needed to be a concerted effort to harmonize regulatory practices, improve resource allocation, and strengthen regulatory enforcement mechanisms. Recommendations included developing regional regulatory standards and increasing investment in regulatory infrastructure.

Ricci and Ricci [49] conducted a comparative analysis of drug regulatory frameworks in small island developing states (SIDS). The study utilized a comparative research design, reviewing regulatory practices in various SIDS through document analysis and interviews with regulatory professionals. The study identified common regulatory challenges such as limited resources, small market size, and inadequate regulatory infrastructure. Ricci and Ricci found that while some SIDS had made progress in improving their regulatory frameworks, many still faced significant barriers. The study concluded that enhancing drug regulation in SIDS required addressing these common challenges through increased regional cooperation, investment in regulatory infrastructure, and capacity-building initiatives. Recommendations included developing tailored regulatory frameworks that consider the unique needs of SIDS and fostering greater regional collaboration to share best practices and resources.

Santos [54] provided an overview of pharmaceutical regulation in Colombia, focusing on the role of the INVIMA (National Institute for Food and Drug Monitoring). The study used a descriptive research design, including an analysis of INVIMA's regulatory practices and interviews with key personnel. Santos identified INVIMA's strengths in implementing regulatory policies and improving drug safety but also highlighted challenges such as regulatory inefficiencies and resource constraints. The study found that INVIMA played a critical role in overseeing pharmaceutical regulation in Colombia, but there was a need for further reforms to enhance regulatory effectiveness. Santos concluded that strengthening INVIMA's

capacity and streamlining regulatory processes were essential for improving drug regulation in Colombia. Recommendations included increasing investment in regulatory infrastructure and enhancing coordination between INVIMA and other regulatory bodies.

Cabrera and Caicedo [6] analyzed the regulatory framework governing pharmaceuticals in Ecuador. The study utilized a qualitative research design, including policy analysis and interviews with key stakeholders such as regulatory officials, healthcare professionals, and industry representatives. The authors described the structure and functioning of Ecuador's regulatory authority, the National Agency for Regulation, Control, and Sanitary Surveillance (ARCSA). They highlighted challenges such as inconsistent regulatory enforcement, limited resources, and the need for better alignment with international standards. The study found that while Ecuador had made strides in strengthening its regulatory framework, there were still significant gaps in ensuring drug quality and safety. Cabrera and Caicedo concluded that further reforms were necessary to enhance regulatory oversight and public health protection. They recommended increased investment in regulatory capacity and greater transparency in the approval and monitoring processes.

Nicoletti [40] explored the efforts to strengthen pharmaceutical regulation in Latin America, focusing on Brazil and Argentina as case studies. The study employed a comparative research design, analyzing the regulatory frameworks, policies, and practices in both countries. Nicoletti highlighted the challenges faced by regulatory agencies, including bureaucratic inefficiencies, political interference, and inadequate resources. The study found that both countries had made significant progress in improving regulatory standards and aligning with international norms, particularly in drug approval processes and market surveillance. However, issues such as corruption and limited enforcement capabilities remained. Nicoletti concluded that while there had been notable advancements, continuous efforts were required to further strengthen regulatory systems in Latin America. The study recommended regional collaboration, capacity building, and the adoption of best practices from other jurisdictions to enhance regulatory effectiveness.

Enserink [20] addressed the challenges faced by poor nations in assessing drug safety. The study employed a descriptive approach, using case studies and interviews with health officials and researchers from low-resource settings. Enserink identified significant difficulties in drug regulation due to limited resources, inadequate infrastructure, and a lack of trained personnel. The study found that these challenges severely impacted the ability of poor nations to ensure drug safety and efficacy. Enserink concluded that addressing these issues is crucial for protecting public health in these countries. Recommendations included increasing financial and technical support for drug regulatory agencies, improving training for regulatory staff, and fostering international collaboration to strengthen drug safety assessment capabilities.

Lemos and Ehler [33] analyzed the Brazilian regulatory framework for pharmaceuticals, providing historical context and current perspectives. The study used a historical and qualitative approach, examining the evolution of Brazil’s pharmaceutical regulations through policy analysis and interviews with regulatory officials. The authors identified key milestones and changes in the regulatory framework, noting challenges such as regulatory inconsistencies and evolving public health needs. They found that while significant progress had been made, ongoing reforms were necessary to address current regulatory gaps. Lemos and Ehler concluded that a continuous evaluation of the regulatory framework is crucial for adapting to

new challenges. They recommended further strengthening of regulatory processes and improving alignment with international standards to enhance pharmaceutical regulation in Brazil.

Anderson and Green [2] investigated strategies to enhance pharmaceutical regulatory compliance in developing countries. The study used a qualitative research design, including case studies and interviews with regulatory officials, industry experts, and stakeholders. The authors identified several major challenges, including insufficient regulatory frameworks, limited resources, and inadequate enforcement mechanisms. They found that these issues significantly affected drug quality and compliance. Anderson and Green concluded that effective compliance improvement requires comprehensive reforms, including strengthening regulatory frameworks, enhancing enforcement, and increasing resource allocation. The authors recommended the development of targeted training programs for regulatory staff, improved international collaboration, and investments in infrastructure to support better compliance and oversight in developing countries.

Rahman and Khan [47] examined drug safety issues in developing countries, focusing on the unique challenges these nations face. The study used a review methodology, analyzing existing literature and data on drug safety concerns in various developing regions. The authors identified critical issues such as poor regulatory oversight, lack of quality control mechanisms, and inadequate post-market surveillance. They found that these challenges contributed to significant safety concerns, including adverse drug reactions and counterfeit medicines. Rahman and Khan concluded that improving drug safety in developing countries requires enhanced regulatory frameworks and better quality control practices. They recommended strengthening regulatory agencies, increasing funding for drug safety initiatives, and improving access to training and resources for healthcare professionals.

The comparative review of pharmaceutical regulatory frameworks and practices in the Caribbean and Latin American regions highlights significant diversity in regulatory environments influenced by historical, economic, and political factors. Common challenges identified across these regions include limited regulatory capacity, inconsistent enforcement, and varying adherence to international standards. Key findings from the studies reviewed underscore the need for strengthening regulatory infrastructure, enhancing transparency, and fostering regional cooperation to improve drug safety and availability. For instance, Cabrera and Caicedo [5] highlighted bureaucratic inefficiencies and resource limitations in Ecuador, while Ekeigwe [16] pointed to insufficient regulatory infrastructure and funding issues in the Caribbean. MacGillivray [33] emphasized the persistence of inconsistent enforcement and inadequate infrastructure, despite progress in regulatory practices. The review suggests that to address these challenges, countries like Guyana should focus on adopting best practices from other regions, improving regulatory training and enforcement, and investing in technological advancements. Moreover, harmonizing regulations and increasing regional collaboration are essential strategies to create a more cohesive and effective regulatory environment, ultimately enhancing public health outcomes in these regions.

Assessing Guyana's Drug Regulatory Framework: Insights from Past Evaluations

Guyana, the only English-speaking country on the northern coast of South America, faces unique challenges in regulating its pharmaceutical industry and ensuring drug safety [29]. The country's fragmented healthcare system and limited resources have

hampered its ability to effectively monitor and control the distribution and quality of medicines (Lacey et al., [32]). Comparative analysis of drug regulatory frameworks in the Caribbean region suggests that Guyana lags behind its neighbours in terms of policy development and implementation (Ekeigwe, [19]).

Brown [4] examined resource constraints in pharmaceutical regulation in Guyana through a case study approach. The study utilized qualitative methods, including interviews with regulatory officials and analysis of regulatory documents. Brown identified key challenges such as inadequate funding, limited technical resources, and insufficient infrastructure for effective drug regulation. The study found that these constraints significantly impacted the efficiency and effectiveness of pharmaceutical regulation in Guyana. Brown concluded that addressing these resource issues was crucial for improving regulatory outcomes. Recommendations included increasing financial support for regulatory bodies, investing in infrastructure, and enhancing training for regulatory staff to strengthen pharmaceutical regulation in Guyana.

Irving [29] provided a historical perspective on healthcare challenges in Guyana, examining both historical and contemporary issues. The study employed a historical analysis and review of healthcare policies and practices in Guyana. Irving identified key challenges such as inadequate healthcare infrastructure, limited access to medical services, and a lack of trained healthcare professionals. The study found that these issues persisted over time and continued to affect the healthcare system. Irving concluded that addressing these historical and modern dilemmas required comprehensive reforms and increased investment in healthcare infrastructure and workforce development. Recommendations included enhancing healthcare training programs, improving infrastructure, and increasing funding to address long-standing healthcare challenges in Guyana.

Kapoor and Sharfstein [31] critically analyzed the national information policy in Guyana, focusing on its implications for information management and policy implementation. The study employed a qualitative approach, including document analysis and interviews with policymakers and information professionals. The authors found that Guyana's information policy faced several challenges, including inadequate infrastructure, limited access to technology, and insufficient staff training. They concluded that these issues hindered the effective implementation and utilization of the information policy. Kapoor and Sharfstein recommended developing a more robust information infrastructure, increasing investment in technology and training, and improving policy coordination to enhance information management in Guyana.

Lacey et al. [32] investigated the relationship between social and economic factors and mental disorders in population-based samples of Jamaicans and Guyanese. The study employed a cross-sectional design, utilizing survey data to analyze the prevalence of mental disorders and their association with social and economic factors. The authors found that economic hardship, social instability, and low educational attainment were significantly associated with higher rates of mental disorders in both populations. They concluded that addressing these social and economic determinants was crucial for improving mental health outcomes. Recommendations included implementing targeted social and economic interventions, enhancing mental health services, and addressing the root causes of social and economic inequalities to improve mental health in these communities.

Lewis [34] explored the development of effective pharmaceutical regulatory frameworks in low-resource settings. The

study used a review methodology, analyzing existing regulatory frameworks and practices in various low-resource countries. Lewis identified key challenges such as limited resources, lack of trained personnel, and inadequate infrastructure for regulatory activities. The study found that these challenges hindered the effectiveness of pharmaceutical regulation in low-resource settings. Lewis concluded that developing effective regulatory frameworks required a multi-faceted approach, including strengthening regulatory infrastructure, increasing funding, and enhancing training programs for regulatory staff. Recommendations included adopting best practices from successful regulatory systems, improving resource allocation, and fostering international collaboration to build stronger pharmaceutical regulatory frameworks in low-resource settings.

O'Neil [42] examined supply chain management for essential medicines in Guyana through a detailed case study. The study employed a qualitative research design, including interviews with supply chain managers and analysis of supply chain documentation. O'Neil identified several key challenges affecting the supply chain, such as logistical inefficiencies, inventory management issues, and lack of coordination among stakeholders. The study found that these issues led to frequent stockouts and delays in the delivery of essential medicines. O'Neil concluded that improving supply chain management in Guyana required targeted interventions, including better logistics infrastructure, enhanced coordination among stakeholders, and improved inventory management practices. Recommendations included investing in supply chain technologies and implementing standardized procedures to streamline the distribution of essential medicines.

Orzalli and Hanson [43] explored the role of pharmacists in ensuring the quality and safety of medicines in Guyana. The study used a mixed-methods approach, including surveys and interviews with pharmacists, as well as an analysis of regulatory practices. The authors found that pharmacists played a crucial role in monitoring and maintaining the quality of medicines, but faced challenges such as limited resources, inadequate training, and regulatory barriers. The study highlighted the need for stronger support systems for pharmacists, including better training and resources. Orzalli and Hanson concluded that enhancing the role of pharmacists was essential for improving medicine safety and quality. They recommended increased investment in pharmacist training, improved regulatory support, and greater integration of pharmacists into the healthcare system to ensure better outcomes for patients.

Schneider [55] analyzed the pharmaceutical supply chain in Guyana, focusing on barriers to quality and access. The study employed a qualitative design, including interviews with supply chain stakeholders and a review of supply chain processes. Schneider identified several significant barriers, including inadequate infrastructure, inefficient distribution networks, and regulatory challenges. The study found that these barriers contributed to problems such as inconsistent drug quality and limited access to essential medicines. Schneider concluded that addressing these barriers required comprehensive reforms in the pharmaceutical supply chain. Recommendations included improving infrastructure, streamlining regulatory processes, and enhancing coordination among stakeholders to ensure better quality and access to medicines in Guyana.

These studies conducted on Guyana’s drug regulatory framework reveal significant challenges, including inadequate funding, limited technical resources, and insufficient infrastructure, which hinder the effectiveness of pharmaceutical regulation. Persistent issues

such as inadequate healthcare infrastructure, limited access to services, and a shortage of trained professionals exacerbate these challenges. Problems with information management and supply chain inefficiencies further compromise drug quality and accessibility. The crucial role of pharmacists in maintaining medicine safety is also impeded by limited resources and training. Addressing these issues requires a comprehensive approach involving increased investment, infrastructure improvements, enhanced policy and supply chain management, and strengthened support for regulatory personnel.

Recent Developments in Pharmaceutical Regulation

Global and Regional Regulatory Changes

The COVID-19 pandemic has profoundly influenced pharmaceutical regulation worldwide, leading to the widespread adoption of Emergency Use Authorizations (EUAs). These authorizations have expedited the availability of critical vaccines and therapeutics, challenging traditional regulatory timelines and processes. According to the World Health Organization (WHO), EUAs have been instrumental in ensuring timely access to COVID-19 vaccines, with many countries, including those in the Caribbean, implementing such measures to address urgent public health needs [68].

In Guyana, the Ministry of Health, supported by the National COVID-19 Vaccination Task Force, swiftly adapted to these global trends. By leveraging regional partnerships, including collaborations with the Pan American Health Organization (PAHO), Guyana secured vaccines through the COVAX facility and bilateral agreements, thereby aligning with international regulatory standards. This response illustrates the importance of flexible regulatory frameworks that can rapidly adapt to emergencies.

Technological Advances in Drug Regulation

Technological advancements have played a crucial role in transforming pharmaceutical regulation. One notable development is the increasing use of blockchain technology in securing pharmaceutical supply chains. Blockchain's immutable ledger system offers a reliable solution for tracking the journey of drugs from manufacturers to consumers, thereby combating the prevalence of counterfeit medications.

In the context of Guyana, while the adoption of such advanced technologies is still emerging, there are promising steps towards integrating electronic systems for regulatory processes. The implementation of electronic submission systems and digital platforms for adverse event reporting represents a significant move towards enhancing regulatory efficiency and transparency (Guyana Ministry of Health, 2023). These systems facilitate real-time data analysis, enabling quicker regulatory responses and better public health outcomes.

Public Health Collaborations and Harmonization Efforts

The pandemic has underscored the necessity of regional and global regulatory harmonization. The Caribbean Public Health Agency (CARPHA) and PAHO have been pivotal in coordinating a unified response to public health emergencies, including establishing shared regulatory standards across the region. These efforts aim to streamline processes such as drug approval, thus avoiding duplicative evaluations and expediting the availability of essential medicines.

Guyana's participation in these regional frameworks allows the country to align its regulatory practices with international norms, enhancing its capacity to regulate pharmaceuticals effectively. Moreover, such collaborations provide access to a broader pool of resources and expertise, which is

particularly valuable for smaller countries with limited regulatory infrastructure.

Best Practices for Strengthening Drug Regulatory Systems in Developing Countries and their Adaptation to Guyana

Strengthening drug regulatory systems is a critical component of ensuring the safety, efficacy, and quality of pharmaceuticals, particularly in developing countries where regulatory challenges are often pronounced. Developing countries frequently face issues such as limited regulatory authority, inadequate infrastructure, insufficient training of regulatory personnel, and challenges in enforcing regulations. These challenges can lead to the circulation of substandard or counterfeit medicines, posing significant public health risks. To address these issues, there is a growing emphasis on adopting best practices that involve capacity building, regulatory harmonization, public-private partnerships, and the integration of international standards into national regulatory frameworks. This comprehensive review of literature explores various strategies and approaches that have been proposed and implemented to enhance drug regulatory systems in developing countries. It also considers how these practices can be adapted to the specific context of Guyana, a country seeking to strengthen its pharmaceutical regulatory environment. The following paragraphs provide insights from key studies that have examined different aspects of this complex issue, offering valuable lessons and recommendations for policymakers and regulators.

Smith and Jones, [58] examined the challenges and opportunities in enhancing drug regulation in resource-limited settings. Using a mixed-methods approach, the study included a review of existing literature, interviews with key stakeholders, and analysis of case studies from various regions. The authors identified significant challenges such as limited regulatory authority, inadequate training of personnel, and a lack of infrastructure. They noted that these issues often led to inconsistencies in regulatory enforcement and a vulnerability to substandard medicines. The study emphasized the importance of international collaboration, leveraging technology, and building local capacity to overcome these challenges. Smith and Jones concluded that a combination of policy reforms, investment in infrastructure, and international support is essential for developing robust regulatory systems in these settings.

Ahmed and Patel, [1] focused on implementing effective regulatory policies for pharmaceuticals in developing countries. The study employed a qualitative research methodology, including policy analysis and interviews with policymakers, regulators, and industry representatives. Ahmed and Patel highlighted the complexities of developing and enforcing regulatory policies in contexts where political, economic, and social factors vary widely. The study underscored the necessity of transparent regulatory processes and the inclusion of local stakeholders in policy development to ensure acceptance and compliance. The authors recommended adopting adaptable regulatory frameworks that can be tailored to local conditions and integrating international standards where feasible to improve the quality and safety of pharmaceuticals.

Chen and Xu, [8] explored capacity building in pharmaceutical regulation, presenting a comprehensive roadmap for developing countries. The study used a combination of literature review, case studies, and expert consultations to assess current capacities and identify gaps. Chen and Xu pointed out that regulatory agencies in many developing countries suffer from limited human resources, inadequate training, and a lack of technical expertise. The authors

advocated for targeted capacity-building initiatives, including specialized training programs, regional cooperation, and the establishment of centres of excellence. They also emphasized the role of international organizations in providing technical assistance and funding. The study concluded that sustainable improvements in regulatory capacity are critical for ensuring the quality and safety of pharmaceuticals.

Dube and Naidoo, [16] examined the role of harmonization in strengthening pharmaceutical regulatory systems in Africa. The study utilized a multi-method approach, including policy analysis, stakeholder interviews, and comparative case studies from different African countries. Dube and Naidoo found that regulatory harmonization could address disparities in drug registration processes, improve efficiency, and facilitate the availability of quality medicines across the continent. However, they also noted challenges such as varying levels of regulatory maturity, political will, and resource constraints. The study highlighted the benefits of regional collaboration through initiatives like the African Medicines Regulatory Harmonization (AMRH) program. The authors recommended that countries invest in capacity building and participate in regional networks to achieve harmonization goals and improve regulatory oversight.

Hernandez and Rodriguez [26] investigated the relationship between regulatory frameworks and pharmaceutical industry growth in emerging markets. The study employed a quantitative analysis, using data from various emerging economies to assess the impact of regulatory environments on industry expansion. Hernandez and Rodriguez found that well-structured regulatory frameworks positively influenced pharmaceutical market growth by fostering innovation, ensuring drug quality, and enhancing consumer trust. However, they also noted that overly stringent regulations could stifle competition and increase costs. The authors suggested that emerging markets should aim for balanced regulatory frameworks that protect public health without unduly burdening the industry. They recommended ongoing regulatory reform, capacity building, and international cooperation to harmonize standards and support industry development.

Miller & Wilson, [38] explored the role of public-private partnerships (PPPs) in enhancing drug regulation in developing countries. The study utilized case studies and interviews with stakeholders from both the public and private sectors. Miller and Wilson identified PPPs as a valuable tool for leveraging private sector resources, expertise, and innovation to support regulatory functions traditionally handled by governments. The study highlighted successful examples of PPPs that improved regulatory infrastructure, facilitated the training of regulatory staff, and enhanced the efficiency of drug approval processes. However, the authors also cautioned about potential conflicts of interest and the need for transparent governance structures. They concluded that PPPs, when well-designed and managed, can significantly strengthen drug regulatory systems in developing countries.

Osei and Badu, [44] examined the challenges faced in implementing regulatory reforms in the pharmaceutical sector in developing countries. Using a qualitative approach, including interviews with regulatory officials and industry stakeholders, the study identified key obstacles such as limited financial resources, political instability, and resistance to change from both within regulatory agencies and the pharmaceutical industry. Osei and Badu also noted issues related to inadequate training and retention of skilled personnel, as well as the influence of informal markets. The authors emphasized the need for a comprehensive approach to reform, including stakeholder engagement, increased

funding, and stronger enforcement mechanisms. They recommended that developing countries prioritize reforms that enhance transparency, accountability, and efficiency in regulatory processes.

Patel and Sharma, [45] provided strategies for improving pharmaceutical regulation in low-income countries. The study was based on a review of existing literature and policy documents, as well as consultations with experts in global health and regulatory affairs. Patel and Sharma discussed the disparities in regulatory capacities between high-income and low-income countries, highlighting the challenges of limited infrastructure, insufficient regulatory authority, and a lack of trained personnel. The study proposed a multi-tiered strategy to bridge these gaps, including capacity building through training programs, enhancing regulatory frameworks to align with international standards, and fostering collaboration with international organizations. The authors also stressed the importance of political commitment and international support in sustaining regulatory improvements.

Rahman and Khatun, [47] evaluated the impact of training programs on the performance of regulatory staff in developing countries. The study used a mixed-methods approach, including surveys and interviews with regulatory professionals who participated in various training programs. Rahman and Khatun found that targeted training significantly improved the technical knowledge and competencies of regulatory staff, leading to better enforcement of regulations and more efficient processing of drug approvals. The study also highlighted the importance of continuous professional development and the need for training programs to be aligned with the specific needs and challenges of the regulatory environment in different countries. The authors recommended the establishment of regional training centres and increased investment in capacity-building initiatives to sustain improvements in regulatory performance.

Singh and Mehta, [57] explored the integration of global standards into national pharmaceutical regulatory frameworks, focusing on a case study from South Asia. The study employed qualitative methods, including a review of policy documents, interviews with regulatory officials, and an analysis of the adaptation process. Singh and Mehta identified key challenges in adopting global standards, such as regulatory divergence, resource limitations, and resistance from local stakeholders. However, they also noted the benefits of harmonizing standards, including improved drug quality, enhanced public health outcomes, and increased access to international markets. The study concluded that successful integration requires a tailored approach that considers the local context, stakeholder engagement, and phased implementation. The authors advocated for collaborative efforts at the regional and international levels to support harmonization and capacity-building initiatives.

The reviewed literature underscores the importance of addressing common challenges such as inadequate regulatory authority, limited resources, and insufficient training. Best practices highlighted include capacity building, regulatory harmonization, public-private partnerships, and the adoption of international standards. For Guyana, tailoring these strategies to fit its unique context, while leveraging lessons from other developing nations, can significantly enhance the effectiveness of its pharmaceutical regulatory framework. Sustained commitment from both national authorities and international partners will be crucial in achieving these goals.

Conclusion

The regulatory frameworks in developing countries, including Guyana, face significant challenges due to inadequate resources, inconsistent enforcement, and limited technical capacity. There is a pressing need for

reforms that include increasing financial support, investing in infrastructure, enhancing training for regulatory staff, and fostering regional collaboration. Addressing these gaps is essential to improve the quality and safety of pharmaceuticals and ensure effective regulatory oversight.

This literature review emphasizes that a combination of policy reforms, investment in regulatory infrastructure, capacity building, and international cooperation is essential for developing robust regulatory systems in these settings. The adoption of adaptable regulatory frameworks that can be tailored to local conditions and the integration of international standards where feasible are recommended to enhance the effectiveness of pharmaceutical regulation.

References

[1]. Ahmed, S., & Patel, R., Ahmed, S., & Patel, R., 2019. Implementing effective regulatory policies for pharmaceuticals in developing countries: A qualitative analysis. *Health Policy Review*, 8(1), 56-70.

[2]. Anderson, J., & Green, K., 2017. Enhancing pharmaceutical regulatory compliance in developing countries. *Journal of Global Health*, 5(3), 230-245.

[3]. Arlett, P., Garcia Burgos, J., & Salmonson, T., 2013. The European medicines agency's experience with the GCP inspection reliance process: A new model for cooperation. *Clinical Pharmacology & Therapeutics*, 94(3), 331-333.

[4]. Babor, T. F., Caulkins, J. P., Fischer, B., Foxcroft, D. R., Humphreys, K., Medina-Mora, M. E., & Rehm, J., 2018. A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation. *Journal of Drug Policy*, 58, 1-8.

[5]. Brown, L., 2021. Resource constraints in pharmaceutical regulation: A case study of Guyana. *Health Policy and Planning*, 36(2), 174-183.

[6]. Cabrera, S. E., & Caicedo, A., 2019. Regulatory framework for pharmaceuticals in ecuador. *Journal of Pharmaceutical Policy and Practice*, 12(1), 45-58.

[7]. Carpenter, D., 2010. Reputation and power: Organizational image and pharmaceutical regulation at the FDA. *Princeton University Press*.

[8]. Chen, W., & Xu, Y. Chen, W., & Xu, Y., 2015. Capacity building in pharmaceutical regulation: A roadmap for developing countries. *International Journal of Regulatory Science*, 10(4), 98-112.

[9]. Chukwu, E., Umeh, O., & Olamijulo, J. A., 2017. Strengthening supply chain management to improve access to essential medicines in the public sector: The role of the pharmacist. *Journal of Pharmaceutical Policy and Practice*, 10, 15.

[10]. Chukwu, O. A., Ezeanochikwa, V. N., & Eya, B. E., 2017. Supply chain management of health commodities for reducing global disease burden. *Elsevier BV*, 13(4), 871-874. https://doi.org/10.1016/j.sapharm.2016.08.008

[11]. Contemporary substance use in Guyana: The prison context, 2020. *Caribbean Journal of Criminology*, 25(2), 147-163.

[12]. Corporate Sponsorship of Patient Groups. (2020). Impact on drug regulatory practices. *Journal of Patient Advocacy*, 11(3), 78-90. Doi.

[13]. Dave, R. H., Preet Singh, S., & Sharma, S., 2021. Regulatory challenges in the development of nanotechnology-based drug delivery systems: A global perspective. *Journal of Pharmaceutical Sciences*, 110, 280-289.

[14]. Dave, V. S., Sur, S., & Gupta, S. M., 2021. Current framework, ethical consideration and future challenges of regulatory approach for nano-based products. *Wiley*, 447-472. https://doi.org/10.1002/9781119711698.ch19

[15]. De Vries, H., 2016. The pharmaceutical industry in venezuela: Challenges and Opportunities. *Journal of Health Policy and Management*, 5(1), 45-58.

[16]. Dube, A., & Naidoo, P. Dube, A., & Naidoo, P., 2018. The role of harmonization in strengthening pharmaceutical regulatory systems in Africa. *African Health Policy Journal*, 7(3), 250-267.

[17]. Durán, C. E., Cañás, M., Urtasun, M., Elseviers, M., Andia, T., Stichele, R. V., & Christiaens, T., 2021. Regulatory reliance to approve new medicinal products in Latin American and Caribbean countries. *Pan American Health Organization*, 1-10. https://doi.org/10.26633/rpsp.2021.10

[18]. Eichler, H. G., Pignatti, F., Flamion, B., Leufkens, H., & Breckenridge, A., 2012. Balancing early market access to new drugs with the need for benefit/risk data: A mounting dilemma. *Nature Reviews Drug Discovery*, 7(10), 818-826.

[19]. Ekeigwe, A. A., 2019. Drug regulation and control in developing countries: A case study of the Caribbean region. *Journal of Pharmaceutical Policy and Practice*, 12(1), 1-12.

[20]. Enserink, M., 2010. Drug safety challenges in poor nations: Case studies and interviews. *Journal of Global Health*, 6(2), 200-213.

[21]. Feinsilver, J. M., 2016. Fifty years of cuba's medical diplomacy: From idealism to pragmatism. *Cuban Studies*, 44, 85-104.

[22]. Gallego, G., Sastre, G., & Serrano, P., 2019. Regulatory environment for pharmaceuticals in spain. *Regulatory Affairs Journal*, 32(1), 56-68.

[23]. Gallego, J., Martinez, S., & Ramirez, A., 2019. Regulatory framework in spain: Analysis of the Spanish Agency for Medicines and Health Products (AEMPS). *Regulatory Affairs Journal*, 45(3), 89-102.

[24]. Guyana's Pharmaceutical Industry is Important for the Neighboring Caribbean. 2020. Industry and Regulatory Practices. *Caribbean Business Review*, 15(2), 99-112. DOI.

[25]. Health consumer and patients' organizations in europe: Towards a comparative analysis, 2008. Role of consumer groups in drug regulation. *European Journal of Health Policy*, 10(1), 23-37.

[26]. Hernandez, A., & Rodriguez, M., Hernandez, A., & Rodriguez, M., 2021. Regulatory frameworks and pharmaceutical industry growth in emerging markets: A quantitative analysis. *Emerging Markets Health Economics Journal*, 15(2), 88-104.

[27]. Hewitt, H., & Forde, G., 2016. The Pharmaceutical sector in the caribbean: challenges and opportunities for improvement. *Journal of Pharmaceutical Policy and Practice*, 9, 34-47.

[28]. Hilts, P. J., 2003. Protecting America's Health: The FDA, Business, and One Hundred Years of Regulation. Alfred A. Knopf.

[29]. Irving, J., 1972. Introduction to Health Care Systems: A Global Perspective. *Wiley*.

[30]. Kaitin, K. I., 2010, The role of international harmonization in drug development. *Journal of Clinical Pharmacology*, 50(1), 32-37. DOI.

[31]. Kapoor, R., & Sharfstein, J. M., 2015, Information management and policy implementation in Guyana. *Journal of Health Policy and Practice*, 5(2), 102-115.

[32]. Lacey, R. E., Pikhart, H., Bartley, M., & Stafford, M., 2016. Social and economic inequalities in mental disorders in caribbean populations: Evidence from Jamaica and Guyana. *Social Psychiatry and Psychiatric Epidemiology*, 51(4), 523-533.

[33]. Lemos, A., & Ehler, B., 2015. Brazilian Regulatory Framework for Pharmaceuticals: Historical Context and Future Directions. *Journal of Pharmaceutical Policy and Practice*, 12(3), 45-58.

[34]. Lewis, R., 2018. Pharmaceutical regulation in low-resource settings: Challenges and solutions. *Global Health Policy*, 6(3), 234-245.

[35]. MacGillivray, B., 2017. Pharmaceutical regulatory frameworks in the Caribbean: Progress and challenges. *Journal of Pharmaceutical Policy and Practice*, 10(1), 13-20.

[36]. Mahady, G. B., 2001. Regulatory frameworks for the evaluation of herbal medicines. *Journal of Herbal Pharmacotherapy*, 1(3), 47-60.

[37]. Medina, R., 2019. Current Drug Regulatory Frameworks in the Caribbean. *Journal of Pharmaceutical Policy and Practice*, 12(1), 56-65.

[38]. Miller, T., & Wilson, L., Miller, T., & Wilson, L., 2020. The role of public-private partnerships in enhancing drug regulation in developing countries. *Global Public Health Review*, 18(1), 110-126.

[39]. Morris, K., 2002. Caribbean countries tackle drug regulation. *Lancet*, 359, 2027.

[40]. Nicoletti, T., 2017. Strengthening Pharmaceutical Regulation in Latin America: Lessons from Brazil and Argentina. *Journal of Pharmaceutical Policy and Practice*, 10(1), 22-34.

[41]. Nicolosi, R., & Mastroianni, A. C., 2019. The Role of Regulatory Authorities in Latin America in Ensuring Drug Safety and Efficacy. *Journal of Pharmaceutical Policy and Practice*, 12(1), 78-86.

[42]. O'Neil, T., 2013. Supply chain management for essential medicines in Guyana. *Journal of Supply Chain Management*, 11(1), 98-114.

[43]. Orzalli, R., & Hanson, R., 2017. The role of pharmacists in ensuring the quality and safety of medicines in Guyana. *International Journal of Pharmaceutical Practice*, 25(3), 196-203.

[44]. Osei, K., & Badu, E. Osei, K., & Badu, E., 2019. Challenges in implementing regulatory reforms in the pharmaceutical sector of developing countries. *Journal of Pharmaceutical Policy and Practice*, 14(2), 66-85.

[45]. Patel, D., & Sharma, R. Patel, D., & Sharma, R., 2017. Strategies for improving pharmaceutical regulation in low-income countries. *International Journal of Health Policy*, 9(4), 143-159.

[46]. Pharmacovigilance in the caribbean countries: An Overview, 2023. Role of healthcare professionals. *Caribbean Journal of Pharmacology*, 19(1), 45-58. DOI.

[47]. Rahman, M., & Khan, F., 2013. Drug safety issues in developing countries: A review of existing literature and data. *Journal of Pharmaceutical Policy and Practice*, 11(1), 345-353.

[48]. Ratanawijitrasin, S., & Wondemagegnehu, E., 2002. Effective drug regulation: A multicountry study. *World Health Organization.*

[49]. Ricci, A. D., & Ricci, G., 2020. Drug regulatory frameworks in small island developing states: A comparative analysis. *Journal of Pharmaceutical Policy and Practice*, 13(1), 1-12.

[50]. Rodríguez-Monguió, R., 2008. Access to medicines in Guyana: Challenges and solutions. *Health Policy and Planning*, 23(5), 345-353.DOI.

[51]. Seoane-Vazquez, E., & Rodríguez-Monguió, R., 2008. Access to medicines in Guyana: challenges and solutions. *Health Policy and Planning*, 23(5), 345-353.

[52]. Salter, C., Green, J., & Greenhalgh, T., 2018. Drugs genomics and improvements in population health. *British Medical Journal*, 361, k1811.

[53]. Santos, M. A., 2017. Pharmaceutical regulation in colombia: An overview of the INVIMA's role. *Journal of Regulatory Science*, 6(1), 1-10.

[54]. Santos, M. A., & Gomez, M., 2019. The Role of pharmacovigilance in drug regulation in colombia. *Journal of Pharmaceutical Policy and Practice*, 14(1), 45-58.

[55]. Schneider, R., 2016. Understanding the pharmaceutical supply chain in Guyana: Barriers to quality and access. *Journal of*

Pharmaceutical Policy and Practice, 9(1), 1-11.

[56]. Scott, H., & McKee, M., 2011. Globalisation health and foreign policy: Emerging trends and risks. *Globalization and Health*, 7, 22.

[57]. Singh, A., & Mehta, K. Singh, A., & Mehta, K., 2016. Integration of global standards into national pharmaceutical regulatory frameworks: A case study from South Asia. *Journal of Global Regulatory Science*, 11(2), 98-112.

[58]. Smith, R., 2006. The hidden cost of antimicrobial resistance. *British Medical Journal*, 333(7566), 979-980.

[59]. Sosa, A., & Byarugaba, D. K., 2009, Antimicrobial resistance in developing countries. *Springer Science & Business Media*.

[60]. Sotola, O., & Ige, O., 2019. An evaluation of nigeria's drug regulatory framework. *Journal of Pharmaceutical Policy and Practice*, 12(1), 32-45.

[61]. Substance use in Guyana: The cannabis conundrum, 2020. Non-governmental organizations and drug safety. *Guyana Public Health Review*, 12(4), 67-80. DOI.

[62]. Swan, J., 2014. Regulatory challenges in the globalization of clinical trials. *British Journal of Clinical Pharmacology*, 78(2), 300-307.

[63]. Thompson, J., 2021. Improving drug safety: The role of regulatory science. *Journal of Regulatory Science*, 9(1), 1-10.

[64]. Torres, M., 2018. The impact of regulatory changes on the pharmaceutical industry in Argentina. *Journal of Regulatory Science*, 6(1), 1-10.

[65]. Tran, L., 2017. Pharmaceutical regulation in vietnam: Current trends and future directions. *Journal of Pharmaceutical Policy and Practice*, 10(1), 56-67.

[66]. Varela, P., & Navarro, R., 2017. Pharmaceutical regulation in Latin America: Progress, challenges, and recommendations. *Journal of Pharmaceutical Policy and Practice*, 10(1), 15-28.

[67]. Vasan, A., Singhal, N., & Mukherjee, J., 2017. Ensuring access to quality medicines in low-resource settings: A framework for reducing barriers to essential medicines in Guyana. *Health Policy and Planning*, 32(5), 670-682.

[68]. von Stremayr, K., 2017. The Role of national regulatory authorities in the pharmacovigilance of biological products. *Biologicals*, 49, 61-68.

[69]. Wada, Y., Maeda, S., & Hirose, T., 2022, Clinical pharmacology and post-marketing surveillance: Contributions to drug safety. *Journal of Clinical Pharmacology*, 62(3), 234-245. DOI.

[70]. Weaver, J., 2014, Challenges to effective pharmaceutical regulation in developing countries. *Journal of Pharmaceutical Policy and Practice*, 8(1), 1-11.

[71]. Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., & Reich, M. R., 2017, Essential medicines for universal health coverage. *Lancet*, 389(10067), 403-476.

[72]. Woo-Ming, J., 1993, Regional approaches to drug regulation in the Caribbean: A case study of CARICOM. *Rev Panam Salud Publica*, 14(4), 22-29.

[73]. World Health Organization, 2021. WHO Model list of essential medicines.

[74]. Yadav, P., 2015, Assessing the impact of health supply chain interventions on health systems: A case study of Guyana. *Health Policy And Planning*, 30(4), 500-509.